Lidocaina Cloridrato S.A.L.F. (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the rapid influx of sodium ions that initiates an action potential. By inhibiting nerve impulse propagation, it temporarily halts transmission of pain signals from the site of administration to the central nervous system.

The dosage is individualized; a qualified healthcare professional selects the amount, concentration, and rate of intravenous administration based on the patient’s age, weight, procedure type, and clinical response. No fixed regimen is provided in public literature.

Safety data are limited; lidocaine crosses the placenta and is excreted in breast milk in small amounts. Use is generally reserved for situations where the benefit outweighs potential risk, and only under medical supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Lidocaine has a rapid onset (1–2 minutes) and intermediate duration (30–120 minutes), making it suitable for many procedures. Compared with bupivacaine, it has a shorter duration and lower cardiotoxicity, while offering faster recovery. Choice depends on required anesthesia depth, procedure length, and patient risk factors.

Store at ambient temperature, preferably below 25 °C, in the original sealed container. Protect from moisture, direct sunlight and extreme temperatures. Do not freeze. Ensure the vial remains upright and check the expiry date before use.

The solution is administered intravenously by a qualified healthcare professional. It may be given as a slow bolus or continuous infusion, depending on the clinical setting. Proper aseptic technique and appropriate monitoring of vital signs are essential during administration.

Serious adverse events include anaphylactic reactions, cardiac arrhythmias such as ventricular tachycardia, and central nervous system toxicity leading to seizures. These risks increase with rapid high‑dose administration or in patients with pre‑existing cardiac or hepatic impairment, requiring immediate medical intervention.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid it. It is also contraindicated in individuals with severe heart block, uncontrolled epilepsy, or significant hepatic dysfunction where metabolism is impaired. Clinical judgment is required for other high‑risk groups.